ClinicalTrials.gg
RecruitingNCT00898638Updated Nov 19, 2026

Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants

An observational study in Head and Neck Cancer, sponsored by Vanderbilt University Medical Center. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Vanderbilt University Medical Center · Observational

How we know

From the registry’s dates

  • Started Feb 2003; still recruiting 23 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
8,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Head and Neck Neoplasms by Vanderbilt University Medical Center — 1 open to participants now, 2 under way, none of them phase 3. Head and Neck Neoplasms · Vanderbilt University Medical Center.

Started
2003
the only one that year
Observational
8 of 12
1 open now
Registered
3rd of 12
by date

Among the 12 studies in Head and Neck Neoplasms by Vanderbilt University Medical Center, this one is the only one that started in 2003, is one of 8 observational ones, and was the 3rd registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

1 of the 12 studies in Head and Neck Neoplasms by Vanderbilt University Medical Center is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Head and Neck Neoplasms by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

RATIONALE: Collecting and storing samples of tissue, saliva, and blood from patients with cancer and from healthy participants to study in the laboratory may help the study of cancer in the future.

PURPOSE: This research study is collecting and storing tissue samples from patients with head and neck cancer and from healthy participants.

Read the detailed description

OBJECTIVES:

  • Maintain and update a clinical database pertaining to diagnosis and treatment outcome of patients with head and neck cancer.
  • Develop a repository of biospecimens from these patients.

OUTLINE: Tumor tissue samples and/or bronchial washings are collected from patients undergoing planned surgery and/or bronchoscopy, respectively. Buccal swabs and/or mouthwash samples and saliva samples are collected. Patients also undergo blood sample collection at baseline and then every 2-6 months thereafter.

Healthy participants contribute blood samples, buccal swabs, and mouthwash samples at baseline only.

Information about medical and family history and cancer risk factors is also collected.

PROJECTED ACCRUAL: No limit.

FOLLOW UP: Indefinite, until date of death or lost to follow up.

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • stage I squamous cell carcinoma of the hypopharynx
  • stage II squamous cell carcinoma of the hypopharynx
  • stage III squamous cell carcinoma of the hypopharynx
  • stage IV squamous cell carcinoma of the hypopharynx
  • recurrent squamous cell carcinoma of the hypopharynx
  • stage I squamous cell carcinoma of the larynx
  • stage I verrucous carcinoma of the larynx
  • stage II squamous cell carcinoma of the larynx
  • stage II verrucous carcinoma of the larynx
  • stage III squamous cell carcinoma of the larynx
  • stage III verrucous carcinoma of the larynx
  • stage IV squamous cell carcinoma of the larynx
  • stage IV verrucous carcinoma of the larynx
  • recurrent squamous cell carcinoma of the larynx
  • recurrent verrucous carcinoma of the larynx
  • stage I adenoid cystic carcinoma of the oral cavity
  • stage I basal cell carcinoma of the lip
  • stage I mucoepidermoid carcinoma of the oral cavity
  • stage I squamous cell carcinoma of the lip and oral cavity
  • stage I verrucous carcinoma of the oral cavity
  • stage II adenoid cystic carcinoma of the oral cavity
  • stage II basal cell carcinoma of the lip
  • stage II mucoepidermoid carcinoma of the oral cavity
  • stage II squamous cell carcinoma of the lip and oral cavity
  • stage II verrucous carcinoma of the oral cavity
  • stage III adenoid cystic carcinoma of the oral cavity
  • stage III basal cell carcinoma of the lip
  • stage III mucoepidermoid carcinoma of the oral cavity
  • stage III squamous cell carcinoma of the lip and oral cavity
  • stage III verrucous carcinoma of the oral cavity
  • stage IV adenoid cystic carcinoma of the oral cavity
  • stage IV basal cell carcinoma of the lip
  • stage IV mucoepidermoid carcinoma of the oral cavity
  • stage IV squamous cell carcinoma of the lip and oral cavity
  • stage IV verrucous carcinoma of the oral cavity
  • recurrent adenoid cystic carcinoma of the oral cavity
  • recurrent basal cell carcinoma of the lip
  • recurrent mucoepidermoid carcinoma of the oral cavity
  • recurrent squamous cell carcinoma of the lip and oral cavity
  • recurrent verrucous carcinoma of the oral cavity
  • metastatic squamous neck cancer with occult primary squamous cell carcinoma
  • recurrent metastatic squamous neck cancer with occult primary
  • untreated metastatic squamous neck cancer with occult primary
  • stage I lymphoepithelioma of the nasopharynx
  • stage I squamous cell carcinoma of the nasopharynx
  • stage II lymphoepithelioma of the nasopharynx
  • stage II squamous cell carcinoma of the nasopharynx
  • stage III lymphoepithelioma of the nasopharynx
  • stage III squamous cell carcinoma of the nasopharynx
  • stage IV lymphoepithelioma of the nasopharynx
  • stage IV squamous cell carcinoma of the nasopharynx
  • recurrent lymphoepithelioma of the nasopharynx
  • recurrent squamous cell carcinoma of the nasopharynx
  • stage I lymphoepithelioma of the oropharynx
  • stage I squamous cell carcinoma of the oropharynx
  • stage II lymphoepithelioma of the oropharynx
  • stage II squamous cell carcinoma of the oropharynx
  • stage III lymphoepithelioma of the oropharynx
  • stage III squamous cell carcinoma of the oropharynx
  • stage IV lymphoepithelioma of the oropharynx
  • stage IV squamous cell carcinoma of the oropharynx
  • recurrent lymphoepithelioma of the oropharynx
  • stage I esthesioneuroblastoma of the paranasal sinus and nasal cavity
  • stage I inverted papilloma of the paranasal sinus and nasal cavity
  • stage I midline lethal granuloma of the paranasal sinus and nasal cavity
  • stage I squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage II esthesioneuroblastoma of the paranasal sinus and nasal cavity
  • stage II inverted papilloma of the paranasal sinus and nasal cavity
  • stage II midline lethal granuloma of the paranasal sinus and nasal cavity
  • stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity
  • stage III inverted papilloma of the paranasal sinus and nasal cavity
  • stage III midline lethal granuloma of the paranasal sinus and nasal cavity
  • stage III squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity
  • stage IV inverted papilloma of the paranasal sinus and nasal cavity
  • stage IV midline lethal granuloma of the paranasal sinus and nasal cavity
  • stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity
  • recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity
  • recurrent inverted papilloma of the paranasal sinus and nasal cavity
  • recurrent midline lethal granuloma of the paranasal sinus and nasal cavity
  • recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity
  • stage I salivary gland cancer
  • stage II salivary gland cancer
  • stage III salivary gland cancer
  • stage IV salivary gland cancer
  • recurrent salivary gland cancer
  • recurrent squamous cell carcinoma of the oropharynx
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Head and neck tumor patients, aged 18 and older and Healthy volunteers, aged 18 and older.

Eligibility criteria

DISEASE CHARACTERISTICS:

  • Meets 1 of the following criteria:

    • Diagnosis of head and neck cancer
    • Being treated at Vanderbilt University Medical Center for the cancer
    • Healthy participant

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
8,000 participants (estimated)
Target follow-up
9999 Days
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Healthy Volunteers

    Non-tumor volunteers will be asked to participate at the time that they are attending a head and neck cancer screening clinic or at the time they are accompanying a patient to their appointment at the head and neck clinic. Intake sheets and biological specimens contributed by volunteers will be coded at the time of collection so that no identifiers are obtained. These specimens will not be linked to identifiers.

    Other: biologic sample preservation procedure · Other: medical chart review

  • Head and Neck Tumor patients

    Eligible patients will be identified at the Vanderbilt Head \& Neck Clinic by clinical and research staff. An appropriately trained staff member will discuss the protocol with the patient (including, risks, benefits, alternatives, etc.).

    Other: biologic sample preservation procedure · Other: medical chart review

Interventions

  • Otherbiologic sample preservation procedure
  • Othermedical chart review
06

What researchers measure

Primary outcomes

  1. Maintenance of a clinical database pertaining to diagnosis and treatment outcome of patients with head and neck cancer

    Collection of data for both groups from the Vanderbilt Otolaryngology Patient Intake questionnaire as well as the medical record, such as medical history, family history, and exposures to risk factors for cancer (tobacco and alcohol use), and results of tests related to diagnosis of tumor and treatment response (for tumor patients only).

    Time frame: ongoing

  2. Development of a repository of biospecimens

    Collection of blood, tissue, saliva, bronchial washings and other specimens as indicated from both tumor and healthy patients.

    Time frame: ongoing

07

Study locations

4 of 4 sites recruiting
  • Vanderbilt-Ingram Cancer Center - Cool Springs
    Nashville, Tennessee 37064, United States
    Recruiting
    • Eben Rosenthal, MD · Contact800-811-8480
  • Vanderbilt-Ingram Cancer Center at Franklin
    Nashville, Tennessee 37064, United States
    Recruiting
    • Eben Rosenthal, MD · Contact800-811-8480
  • Veterans Affairs Medical Center - Nashville
    Nashville, Tennessee 37212, United States
    Recruiting
    • Clinical Trials Office - Veterans Affairs Medical Center - Nas · Contact615-327-4751
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232-6838, United States
    Recruiting
    • Clinical Trials Office - Vanderbilt-Ingram Cancer Center · Contact800-811-8480
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2003 (actual). Primary completion is estimated for Dec 2050, 574 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2009
First posted
May 12, 2009
StartActual
Feb 13, 2003
Primary completionEst.
Dec 2050
CompletionEst.
Dec 2050
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00898638
Responsible party
Eben Rosenthal (Dept Chairperson Professor, Vanderbilt University Medical Center) — Principal investigator
First posted
May 12, 2009
Start date
Feb 13, 2003
Primary completion
Dec 2050 (estimated)
Completion
Dec 2050 (estimated)
Last update
Nov 19, 2026

Study contacts

Brandee Brown
Contact
brandee.t.brown@vumc.org
615-936-4896
Eben Rosenthal, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion